Hans-Peter Holthoff studied chemistry in Würzburg and received his PhD in molecular genetics in Konstanz. From 2000 to 2007 he worked in the biotech company ProCorde until its merger with Trigen plc, London as scientific project leader in the field of target validation in cardiovascular diseases. From 2007 onwards he took over the scientific management first at Corimmun GmbH which was sold to Janssen-CILAG/Johnson & Johnson in 2012 and later at advanceCOR GmbH until 2020. In addition to his activities as a test manager for the GLP area, Hans-Peter Holthoff was mainly active in the field of personalized diagnostics and in clinical drug development in the field of atherosclerosis and heart failure. Hans-Peter Holthoff joined ISAR Bioscience in 2021 as CTO.